Ferring Korea and Chong Kun Dang announced on the 11th that they have signed a joint sales contract for 'Nocdurna Sublingual Tab (Desmopressin acetate)', a treatment for nocturia.

Following the signing of this contract, Ferring Korea will be in charge of marketing for general hospitals from the 18th, and Chong Kun-dang will be in charge of sales and marketing on clinics.

Ferring Korea and Chong Kun Dang have been jointly selling Minirin, a treatment for nocturia since 2019. Nocdurna with an additional contract is Minirin's low-dose product. Nocdurna improves the symptoms of nocturia caused by polyuria at night, which accounts for up to 88% of the causes of nocturia. It is a new treatment